Literature DB >> 31104729

Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.

James Love-Koh1, Richard Cookson2, Nils Gutacker2, Thomas Patton2, Susan Griffin2.   

Abstract

BACKGROUND: Health inequalities can be partially addressed through the range of treatments funded by health systems. Nevertheless, although health technology assessment agencies assess the overall balance of health benefits and costs, no quantitative assessment of health inequality impact is consistently undertaken.
OBJECTIVES: To assess the inequality impact of technologies recommended under the NICE single technology appraisal process from 2012 to 2014 using an aggregate distributional cost-effectiveness framework.
METHODS: Data on health benefits, costs, and patient populations were extracted from the NICE website. Benefits for each technology were distributed to social groups using the observed socioeconomic distribution of hospital utilization for the targeted disease. Inequality measures and estimates of cost-effectiveness were compared using the health inequality impact plane and combined using social welfare indices.
RESULTS: Twenty-seven interventions were evaluated. Fourteen interventions were estimated to increase population health and reduce health inequality, 8 to reduce population health and increase health inequality, and 5 to increase health and increase health inequality. Among the latter 5, social welfare analysis, using inequality aversion parameters reflecting high concern for inequality, indicated that the health gain outweighs the negative health inequality impact.
CONCLUSIONS: The methods proposed offer a way of estimating the health inequality impacts of new health technologies. The methods do not allow for differences in technology-specific utilization and health benefits, but require less resources and data than conducting full distributional cost-effectiveness analysis. They can provide useful quantitative information to help policy makers consider how far new technologies are likely to reduce or increase health inequalities.
Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  distributional cost-effectiveness analysis; economic evaluation; health equity; health inequality; health technology assessment

Mesh:

Year:  2019        PMID: 31104729     DOI: 10.1016/j.jval.2019.03.006

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  9 in total

1.  Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study.

Authors:  Sebastian Hinde; Dan Howdon; James Lomas; Matthew Franklin
Journal:  Appl Health Econ Health Policy       Date:  2022-06-29       Impact factor: 2.561

2.  Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.

Authors:  Thomas Ward; Ruben E Mujica-Mota; Anne E Spencer; Antonieta Medina-Lara
Journal:  Pharmacoeconomics       Date:  2021-10-29       Impact factor: 4.981

3.  Protocol for an economic evaluation and budget impact assessment of a randomised, stepped-wedge controlled trial for practice change support to increase routine provision of antenatal care for maternal alcohol consumption.

Authors:  Penny Reeves; Zoe Szewczyk; Melanie Kingsland; Emma Doherty; Elizabeth Elliott; Adrian Dunlop; Andrew Searles; John Wiggers
Journal:  Implement Sci Commun       Date:  2020-10-15

4.  Impact of Socioeconomic Differences on Distributional Cost-effectiveness Analysis.

Authors:  Fan Yang; Colin Angus; Ana Duarte; Duncan Gillespie; Simon Walker; Susan Griffin
Journal:  Med Decis Making       Date:  2020-07-01       Impact factor: 2.583

5.  Distributional impact of the Malawian Essential Health Package.

Authors:  Matthias Arnold; Dominic Nkhoma; Susan Griffin
Journal:  Health Policy Plan       Date:  2020-07-01       Impact factor: 3.344

Review 6.  Methods to promote equity in health resource allocation in low- and middle-income countries: an overview.

Authors:  James Love-Koh; Susan Griffin; Edward Kataika; Paul Revill; Sibusiso Sibandze; Simon Walker
Journal:  Global Health       Date:  2020-01-13       Impact factor: 4.185

7.  Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic.

Authors:  Yumi Asukai; Andrew Briggs; Louis P Garrison; Benjamin P Geisler; Peter J Neumann; Daniel A Ollendorf
Journal:  Pharmacoeconomics       Date:  2021-09-24       Impact factor: 4.981

8.  Can Real-World Evidence Help Restore Decades of Health Inequalities by Informing Health Care Decision-Making? Certainly, and Here is How.

Authors:  Grammati Sarri
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

9.  Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems.

Authors:  Beth Woods; Aimée Fox; Mark Sculpher; Karl Claxton
Journal:  Health Econ       Date:  2021-08-02       Impact factor: 2.395

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.